Search Results - "Gampenrieder, SP"

Abstract P3-10-07: A 3-gene DNA methylation signature fails to predict response to bevacizumab in metastatic breast cancer patients treated within the TANIA phase III trial by Gampenrieder, SP, Angela, R, Rinnerthaler, G, Hackl, H, Steiner, M, Pulverer, W, Weinhaeusel, A, Klinglmayr, E, Karl, T, Ilic, S, Hufnagl, C, Hauser-Kronberger, C, Egle, A, Greil, R

“…Background: Biomarkers predicting response to bevacizumab containing therapy in metastatic breast cancer (MBC) are of urgent need. In a retrospective…”
Get full text

Abstract OT3-07-01: Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, an ongoing phase I/II trial (AGMT MBC-10 trial) by Rinnerthaler, G, Gampenrieder, SP, Petzer, A, Burgstaller, S, Voskova, D, Rossmann, D, Balic, M, Egle, D, Rumpold, H, Singer, CF, Petru, E, Melchardt, T, Ulmer, H, Mlineritsch, B, Greil, R

“…Background:Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with poor prognosis. Recently, the…”
Get full text

Treatment Landscape for Patients with HER2-Positive Metastatic Breast Cancer: A Review on Emerging Treatment Options by Gampenrieder, Simon Peter, Castagnaviz, Vanessa, Rinnerthaler, Gabriel, Greil, Richard

“…The prognosis of HER2-positive metastatic breast cancer (MBC) has radically changed in recent years and continues to improve due to the broad application of…”
Get full text

Abstract P6-07-10: DNA methylation signature predicting bevacizumab efficacy in metastatic breast cancer by Gampenrieder, SP, Rinnerthaler, G, Pulverer, W, Weinhäusel, A, Hufnagl, C, Hackl, H, Hauser-Kronberger, C, Mlineritsch, B, Greil, R

“…Background: Biomarkers predicting response to bevacizumab containing therapy in breast cancer are still missing. Since epigenetic modifications can contribute…”
Get full text

Abstract P5-15-13: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Final PFS results of a phase II trial (AGMT MBC-6) by Rinnerthaler, G, Gampenrieder, SP, Voskova, D, Petzer, A, Hubalek, M, Petru, E, Hartmann, B, Andel, J, Balic, M, Melchardt, T, Ulmer, H, Mlineritsch, B, Greil, R

“…Background: Capecitabine is a well-established treatment option in HER2-negative advanced breast cancer (ABC) patients. Bendamustine is a generally well…”
Get full text

Abstract OT2-07-11: Ixazomib in combination with carboplatin in pretreated women with advanced triple negative breast cancer, a phase I/II trial (AGMT MBC-10 trial) by Rinnerthaler, G, Gampenrieder, SP, Petzer, A, Pusch, R, Fridrik, M, Rossmann, D, Balic, M, Egle, D, Rumpold, H, Singer, C, Bartsch, R, Melchardt, T, Ulmer, H, Mlineritsch, B, Greil, R

“…Background: Triple-negative breast cancer (TNBC) comprises a heterogeneous group of diseases which are generally associated with a poor prognosis. Up to now,…”
Get full text

Abstract P4-02-02: Contrast-enhanced MRI does not accurately predict pathologic complete response (pCR) after neoadjuvant chemotherapy in early or locally advanced breast cancer by Gampenrieder, SP, Peer, A, Weismann, C, Meissnitzer, M, Rinnerthaler, G, Webhofer, J, Westphal, T, Popovscaia, M, Meissnitzer, T, Reitsamer, R, Hauser-Kronberger, C, Egger, H, Hergan, K, Mlineritsch, B, Greil, R

“…Background: Patients with early or locally advanced breast cancer achieving a pathologic complete response (pCR) after neoadjuvant chemotherapy have a lower…”
Get full text

Abstract P3-07-43: DNA methylation patterns correlating with outcome in patients treated with first-line bevacizumab for metastatic breast cancer by Gampenrieder, SP, Rinnerthaler, G, Weinhäusel, A, Pulverer, W, Hugnagl, C, Hackl, H, Romeder, F, Monzo Fuentes, C, Hauser-Kronberger, C, Mlineritsch, B, Greil, R

“…Background: Biomarkers predicting response to bevacizumab containing therapy in breast cancer are of urgent need for a personalized treatment approach. DNA…”
Get full text

Abstract P1-13-10: Capecitabine in combination with bendamustine in pretreated women with HER2-negative metastatic breast cancer: Stage 1 results of a phase II trial (AGMT MBC-6) by Rinnerthaler, G, Gampenrieder, SP, Fridrik, M, Petzer, A, Hubalek, M, Petru, E, Jäger, T, Andel, J, Balic, M, Ulmer, H, Mlineritsch, B, Greil, R

“…Background: Although there is no single accepted standard of care after failure of anthracycline and taxane therapy in HER2-negative metastatic breast cancer,…”
Get full text

Abstract P1-08-32: Endothelin-1 genetic polymorphism as predictive marker for bevacizumab in metastatic breast cancer by Gampenrieder, SP, Hufnagl, C, Brechelmacher, S, Huemer, F, Hackl, H, Rinnerthaler, G, Romeder, F, Muß, C, Pircher, M, Ressler, S, Kronberger, C, Mlineritsch, B, Greil, R

“…Background: Biomarkers predicting response or toxicity of bevacizumab containing therapy in breast cancer are of urgent need. The genetic variability of VEGF,…”
Get full text

Abstract P5-20-11: Bevacizumab in metastatic breast cancer: a retrospective matched-pair analysis by Gampenrieder, SP, Romeder, F, Muß, C, Pircher, M, Ressler, S, Rinnerthaler, G, Bartsch, R, Sattlberger, C, Mlineritsch, B, Greil, R

“…Background: In November 2011 the FDA withdrew accelerated approval of the breast cancer indication for bevacizumab, because “the drug has not been shown to be…”
Get full text